Anti-HIV and anti-inflammatory action of iodine-lithium-α-dextrin is accompanied by the improved quality of life in AIDS patients

Authors: Mkhitaryan, Levon M.¹; Davtyan, Tigran K.¹; Gabrielyan, Emil S.²; Gevorkyan, Levon A.³

Source: International Journal of Biotechnology, Volume 9, Numbers 3-4, 27 June 2007 , pp. 301-317(17)

Buy & download fulltext article:

Price: $45.55 plus tax (Refund Policy)

Abstract:

Clinical efficacy, tolerability and safety of various doses of Iodine-Lithium-α-Dextrin (ILαD) monotherapy have been evaluated in 56 HIV-infected patients enrolled in double blind uncontrolled randomised study during 48 weeks follow-up period. ILαD was administered intravenously three times over five days with intervals of 2 3 weeks between treatments for a total of 12 infusions in 4 cycles. HIV-1 RNA reduction and increase of CD4+ T-cell counts as well as decrease of serum levels of IgG, IgA, β2 microglobulin, tumour necrosis factor-α and soluble interleukin-2 receptor were observed on 4 24th weeks. Quality of life was dramatically improved on 4 48th weeks and more. The side-effects were phlebitis of punctured small veins and subfebrile fever, that did not lead to discontinuation of the treatment and did not require special treatment. ILαD appears to be safe and can be used as an adjuvant therapy for long term improvement of quality of life in AIDS patients.

Keywords: TECHNICAL JOURNALS; Biosciences and Bioinformatics; ENVIRONMENTAL JOURNALS; Environment and Sustainable Development

Document Type: Research article

DOI: http://dx.doi.org/10.1504/IJBT.2007.014252

Affiliations: 1: Laboratory of Immunology and Virology, Armenicum Research Center, CJSC Armenicum+, 37 Nalbandyan Street, Yerevan 375001, Republic of Armenia. 2: Drug and Medical Technology Agency of Ministry of Health, Yerevan, Republic of Armenia. 3: CJSC Armenicum+, 37 Nalbandyan Street, Yerevan 375001, Republic of Armenia

Publication date: 2007-06-27

More about this publication?

The International Journal of Biotechnology provides an international forum and refereed authoritative source of information in the field of Biotechnology and Biotechnics, with emphasis on management and economics, as well as the political and social issues. It aims to disseminate knowledge, provide a learned reference in the field, and establish channels of communication between academic and research experts, policy makers and executives in industry, commerce and investment institutions.
Information for Authors
Submit a Paper
Subscribe to this Title
Terms & Conditions
Newsletter
Blog
ingentaconnect is not responsible for the content or availability of external websites